Category - Developments

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has filed a final short form prospectus in connection with its previously announced offering of a minimum of $5-million and a maximum of $10-million principal amount of 8%...

Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.” The article said Titan’s Probuphine implant for the treatment of...

IntelGenx (OTCQX:IGXT; TSXV:IGX;) has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled, “Solid oral film dosage forms and methods for making same.” The platform...

Stryker (NYSE:SYK) has agreed to acquire Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) for $11.75 a share, implying a total equity value of approximately $701-million. The transaction price represents a premium of...

Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada. Knight and...

The clinical trial component of 3D Signatures’ (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) Hodgkin’s lymphoma test (Telo-HL) validation program is under way. This process is referred to as Stage 3 of the validation program...

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has received a patent from the United States Patent and Trademark Office entitled, “Film dosage form with extended release mucoadhesive particles.” The patent...

The U.S. Patent and Trademark Office issued a Notice of Allowance for closely held Blue Spark Technologies’ patent application referred to as, “body temperature logging patch,” or its brand name, TempTraq. The wearable...

Closely held Implandata Ophthalmic Products of Germany has received CE Mark for its EYEMATE system, making it available for commercial use within the EU. The EYEMATE system provides intraocular pressure (IOP) readings...

Quidel (NASDAQ:QDEL) has acquired the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for about $14-million. InflammaDry is the only point-of-care test that detects elevated levels of MMP-9, a key...